10192017Headline:

Alere Announces Update on Form 10-K and Provides Preliminary Unaudited Financial Results

May 22, 2017 - (Newswire)

- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced certain preliminary unaudited financial information for the fourth quarter and full fiscal year ended December 31, 2016 and the first quarter of 2017 ended March 31, 2017. The Company also provided an update on its expected filing of its 2016 Annual Report on Form 10-K and filed its preliminary proxy statement with respect to the pending merger with Abbott Laboratories.

The following amounts are preliminary, unaudited and are subject to change and reflect the impact of the Restatement (as defined below) adjustments identified to date, as described further below:

Preliminary Unaudited Full Year 2016 Results

  • Revenue for the full year 2016 is expected to be $2.38 billion, which would be a decrease from $2.45 billion in full year 2015.
  • GAAP loss from continuing operations is expected to be $(140) million, or $(1.86) per diluted share, for the full year 2016.
  • Non-GAAP organic growth for the full year 2016 is expected to be +0.3% or +2.5% excluding Arriva*.
  • Non-GAAP adjusted EBITDA is expected to be $344 million for the full year 2016, including approximately $135 million in merger-related costs, audit and legal fees related to ongoing investigations and legal settlements, as detailed in the Supplemental Financial Information table.

*During the period from November 4, 2016 to December 31, 2016, the Company furnished $9.8 million of Arriva products and services that were subject to the CMS revocation to customers but did not recognize any revenue for such products and services because they were not eligible for reimbursement by CMS at the time the Company furnished them.

Preliminary Unaudited Fourth Quarter 2016 Results

  • Total revenue is expected to be $597 million, which would be a decrease from $617 million in the prior year period.
  • Reported GAAP loss from continuing operations during the fourth quarter of 2016 is expected to be $(117) million, or $(1.41) per diluted share.
  • Non-GAAP organic growth during the fourth quarter of 2016 is expected to be -0.9%, or +3.7% excluding Arriva.
  • Non-GAAP adjusted EBITDA is expected to be $79 million in the fourth quarter of 2016, which includes approximately $50 million in merger-related costs, audit and legal fees related to ongoing investigations and legal settlements, as detailed in the Supplemental Financial Information table.

Preliminary Unaudited First Quarter 2017 Results

  • Total revenue is expected to be $588 million.
  • Non-GAAP organic growth is expected to be +0.9%, or +6.8% excluding Arriva.

Update on Annual Report 2016 Form 10-K
As previously disclosed, the Company was delayed in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2016 due to the Company's review of certain revenue transactions in the Company's South Korea and Japan locations. Based on this review, the Company determined that it had incorrectly recorded certain revenue transactions at its Standard Diagnostics subsidiary in South Korea. Specifically, the Company failed to correctly apply U.S. GAAP regarding the timing of revenue recognition primarily relating to transactions in which the Company recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer as required by U.S. GAAP. The principal cause of these misstatements in the timing of revenue recognition was inappropriate conduct at the Company's Standard Diagnostics subsidiary. As also previously disclosed, as a result of this review, the Company will be restating certain previously issued financial statements (the "Restatement").

The Company has completed its review of the above matters at its South Korea and Japan locations and, consistent with its prior expectation, the Company expects the following adjustments to previously reported financial information as set forth in the tables below. In addition, the Restatement reflects corrections for certain other misstatements that the Company identified in 2017 relating to 2014, 2015 and 2016. These adjustments relate to (a) misstatements in the classification of certain amounts between current assets, noncurrent assets and current liabilities, (b) misstatements in the classification of certain legal-related charges between non-operating expenses and operating expenses, and (c) misstatements to general and administrative expenses to correct the timing of bad debt expenses and fair value adjustments related to contingent consideration liabilities from acquisitions. These adjustments are incorporated into the tables below.

Annual Restatement Impact
(in millions)

Nine Months
Ended September
30, 2016

Twelve Months
Ended December
31, 2015

Twelve Months
Ended December
31, 2014

Twelve Months
Ended December
31, 2013






Revenue

$ 8

$ (8)

$ 2

$ (1)

Pre-Tax Income

$ (1)

$ (4)

$ 0

$ 1

Net Income

$ (0)

$ (3)

$ 0

$ 0











2015 Quarterly Restatement
Impact (in millions)

Three Months
Ended March 31,
2015

Three Months
Ended June 30,
2015

Three Months
Ended September
30, 2015

Three Months
Ended December
31, 2015






Revenue

$ (3)

$ (1)

$ 1

$ (6)

Pre-Tax Income

$ (1)

$ (0)

$ 1

$ (4)

Net Income

$ (0)

$ (0)

$ 1

$ (3)











2016 Quarterly Restatement
Impact
(in millions)

Three Months
Ended March 31,
2016

Three Months
Ended June 30,
2016

Three Months
Ended September
30, 2016







Revenue

$ 9

$ (1)

$ (0)


Pre-Tax Income

$ 4

$ 2

$ (6)


Net Income

$ 4

$ 2

$ (6)







NOTE: The ($6) million pre-tax income impact for the Three Months Ended September 30, 2016 includes $4.4M of expense related to fair value adjustments for contingent consideration.

In addition, as the Company disclosed on May 11, 2017, it is in the process of reviewing sales transactions to a limited number of distributors from select selling entities during fiscal years 2012 to 2016 to determine if revenue recognition timing was appropriate according to U.S. GAAP with respect to collectability being reasonably assured at the time of sale. This review relates to the timing of the recognition of the revenue and not to the existence or measurement of revenue for these transactions and the selling entities being reviewed have historical collection rates in excess of 99.5%.

The Company's goal is to complete its review and file its 2016 Annual Report on Form 10-K by no later than June 15, 2017.

The review necessary to complete the 2016 Annual Report on Form 10-K is not complete. The time necessary to review the foregoing matter may take longer than the Company expects, which would cause a further delay in the filing of the Annual Report beyond the projected filing date noted above. In the course of this ongoing review of revenue recognition and the completion of the review necessary to file the Annual Report, the Company may identify other matters that require additional time to review, which other matters may be similar or different to those identified above. In addition, any of these other items may require the Company to further adjust previously reported financial information, and such adjustments may be material in amount.

Information Regarding Preliminary Unaudited Results
The financial results presented in this release are preliminary and may change. These preliminary results include calculations that have been prepared by Alere management and have not been reviewed or audited by our independent registered public accounting firm. There can be no assurance that Alere's actual financial results will not materially differ from the preliminary unaudited financial data presented herein. Actual results may differ for a number of reasons, including the impact of any changes that may be required as a result of the ongoing review by Alere of revenue recognition and other adjustments that may be made in connection with the finalization of the fiscal year 2016 financial statements and the finalization of the financial statements for the three months ended March 31, 2017 (which may also impact the financial results for any other period presented herein). In addition, the preliminary unaudited financial data presented for the periods ended December 31, 2016 and March 31, 2017 should not be viewed as a substitute for the full financial information prepared in accordance with U.S. GAAP, including footnotes, which is expected to be filed with the SEC as soon as practicable. Please see the "2016 Form 10-K Update" and "Cautionary Statement Regarding Forward-Looking Statements" sections of this press release for further information.

Non-GAAP Information
To supplement the financial measures prepared in accordance with U.S. GAAP, the Company uses Non-GAAP adjusted EBITDA and organic growth, which are non-GAAP financial measures. The reconciliations of Non-GAAP adjusted EBITDA to net income (loss) from continuing operations and organic growth to revenue, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, is shown in the table in this press release. The Company believes Non-GAAP adjusted EBITDA and organic growth are useful to investors because these metrics are commonly used by investors to assess the unleveraged, pre-tax financial performance and operating results of ongoing business operations. The Company's management also uses Non-GAAP adjusted EBITDA and organic growth because the Company's management also believes that these are useful measures to evaluate the performance of the Company based on operational factors. It should also be noted that not all companies calculate Non-GAAP adjusted EBITDA and organic growth in the same manner and, accordingly, these measures presented in this press release may not be comparable to similar measures used by other companies.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as "preliminary", "may," "could," "should," "would," "intend," "will," "expect," "anticipate," "believe," "estimate," "can," "continue" or similar words. A number of important factors could cause actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, (i) the risk that the proposed merger with Abbott Laboratories ("Abbott") may not be completed in a timely manner or at all; (ii) the failure to receive, on a timely basis or otherwise, the required approval of the proposed merger with Abbott by Alere's stockholders, (iii) the possibility that competing offers or acquisition proposals for Alere will be made; (iv) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement and Plan of Merger, as amended (the "Merger Agreement") among Alere and Abbott pursuant to which Abbott will acquire Alere, including in circumstances which would require Alere to pay a termination fee or other expenses; (vi) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on Alere's ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (vii) risks related to diverting management's attention from Alere's ongoing business operations; (viii) the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability, (ix) the risk that the previously announced review of certain aspects of revenue recognition is not completed in a timely manner or the scope of such review expands, (x) the risk that the failure by Alere to file its Form 10-K for the fiscal year ended December 31, 2016 and Form 10-Q for the fiscal quarter ended in March 31, 2017 in a timely manner could lead to the acceleration of the maturity of certain of Alere's indebtedness, (xi) the possibility that the previously announced review of certain aspects of revenue recognition uncovers an additional error or errors in revenue recognition or other financial information which require additional adjustments which may be material, or material weaknesses in the Company's internal controls over financial reporting, (xii) the risk that the Company experiences an acceleration of amounts due under its senior secured credit facility due to the restatement, any circumstances described in Alere's Current Report on Form 8-K as filed on April 17, 2017, this Current Report on Form 8-K or the failure to timely file the Annual Report on Form 10-K for 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2017 (or that the Company could be required to obtain a waiver under such credit agreement), (xiii) risks relating to the ongoing investigations by the United States Securities and Exchange Commission (the "SEC") and the United States Department of Justice, (xiv) the risk that these or other risk factors impact the expected timing of the filing of the Form 10-K for the fiscal year ended December 31, 2016 and Form 10-Q for the fiscal quarter ended in March 31, 2017, and (xv) the risk factors detailed in Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (as filed with the SEC on August 8, 2016) and other risk factors identified herein or from time to time in our periodic filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this communication. The Company undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

About Alere
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters.™ Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.

Alere Inc. and Subsidiaries

Preliminary Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)














Three Months Ended December 31,


Twelve Months Ended December 31,




2016


2015


2016


2015











Net product sales and services revenue


$ 592,553


$ 613,850


$ 2,364,337


$ 2,438,638

License and royalty revenue


4,256


3,286


11,998


16,977


Net revenue


596,809


617,136


2,376,335


2,455,615

Cost of net revenue


325,648


368,586


1,286,468


1,347,315


Gross profit


271,161


248,550


1,089,867


1,108,300


Gross margin


45%


40%


46%


45%











Operating expenses:










Research and development


25,184


28,228


112,122


119,453


Selling, general and administrative


264,283


229,877


969,683


808,595


Impairment and (gain) loss on disposition, net


-


8,132


(3,810)


50,540


Operating income


(18,306)


(17,687)


11,872


129,712

Interest and other income (expense), net


(32,137)


(60,482)


(167,122)


(214,254)


Loss from continuing operations before provision (benefit) for income taxes


(50,443)


(78,169)


(155,250)


(84,542)

Provision (benefit) for income taxes


83,762


(51,146)


35,376


(53,564)


Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of
tax


(134,205)


(27,023)


(190,626)


(30,978)

Equity earnings of unconsolidated entities, net of tax


17,200


5,210


50,505


15,530


Income (loss) from continuing operations


(117,005)


(21,813)


(140,121)


(15,448)


Income from discontinued operations, net of tax


-


2,736


-


219,513

Net income


(117,005)


(19,077)


(140,121)


204,065


Less: Net income attributable to non-controlling interests


(103)


(5)


350


381

Net income attributable to Alere Inc. and Subsidiaries


(116,902)


(19,072)


(140,471)


203,684












Preferred stock dividends


(5,367)


(5,367)


(21,350)


(21,293)











Net income available to common stockholders


$ (122,269)


$ (24,439)


$ (161,821)


$ 182,391












Basic net income per common share:










Income (loss) from continuing operations


$ (1.41)


$ (0.31)


$ (1.86)


$ (0.43)


Income from discontinued operations


-






2.57


Basic and diluted net income per common share


$ (1.41)


$ (0.31)


$ (1.86)


$ 2.14












Diluted net income per common share:










Income (loss) from continuing operations


$ (1.41)


$ (0.31)


$ (1.86)


$ (0.43)


Income from discontinued operations


-




-


2.57


Diluted net income per common share


$ (1.41)


$ (0.31)


$ (1.86)


$ 2.14











Weighted average shares - basic


86,955


85,953


86,796


85,420

Weighted average shares - diluted


86,955


85,953


86,796


85,420

Alere Inc. and Subsidiaries

Preliminary Unaudited Condensed Consolidated Balance Sheets

(in thousands)






December 31,


December 31,


2016


2015

ASSETS




CURRENT ASSETS:




Cash and cash equivalents1

$ 567,215


$ 502,200

Restricted cash

51,550


5,694

Marketable securities

76


164

Accounts receivable, net

413,535


436,924

Inventories, net

308,920


350,949

Prepaid expenses and other current assets

118,607


114,514

Assets held for sale

-


4,165

Total current assets

1,459,903


1,414,610





Property, Plant and Equipment, net

441,190


446,039

Goodwill and other intangible assets, net

3,592,107


3,862,306

Restricted Cash- non-current

2,171


43,228

Other non-current assets

152,908


138,640

Assets held for sale - non-current

-


13,337

Total assets

$ 5,648,279


$ 5,918,160





LIABILITIES AND STOCKHOLDERS' EQUITY




CURRENT LIABILITIES:




Short-term debt and current portions of long-term debt and capital lease obligations

$ 85,434


$ 203,954

Liabilities related to assets held for sale

-


363

Other current liabilities

593,574


518,389

Total current liabilities

679,008


722,706





LONG-TERM LIABILITIES:




Long-term debt and capital lease obligations, net of current portions

2,865,426


2,838,347

Deferred tax liabilities

119,098


147,618

Other long-term liabilities

155,992


154,193

Liabilities related to assets held for sale - non-current

-


-

Total long-term liabilities

3,140,516


3,140,158





TOTAL EQUITY

1,828,755


2,055,296

Total liabilities and equity

$ 5,648,279


$ 5,918,160

















1) As of December 31, 2016 the Company held $567M of cash and cash equivalents, $172M was held by domestic subsidiaries and $395M was held by foreign entities.

Alere Inc. and Subsidiaries

Preliminary Unaudited Selected Consolidated Revenues

(in thousands)











Three Months Ended December 31,



% Change




2016


2015



2016 v. 2015


Professional diagnostics segment (1)








Cardiometabolic

$ 143,569


$ 180,163



-20%


Infectious disease

211,509


188,609



12%


Toxicology

147,785


149,540



-1%


Other

38,020


44,927



-15%



Total professional diagnostics segment

540,883


563,239



-4%


Consumer diagnostics segment (1)

17,569


19,768



-11%


Other Non-reportable

34,101


30,843



11%


License and royalty revenue

4,256


3,286



30%



Net revenue

$ 596,809


$ 617,136



-3%






























Twelve Months Ended December 31,



% Change




2016


2015



2016 v. 2015


Professional diagnostics segment (1)








Cardiometabolic

$ 622,468


$ 703,553



-12%


Infectious disease

776,153


710,178



9%


Toxicology

608,635


618,362



-2%


Other

140,426


192,321



-27%



Total professional diagnostics segment

2,147,682


2,224,414



-3%


Consumer diagnostics segment (1)

74,152


85,128



-13%


Other Non-reportable

142,503


129,096



10%


License and royalty revenue

11,998


16,977



-29%



Net revenue

$ 2,376,335


$ 2,455,615



-3%





























(1) Revenues have been restated for the impact of restatement adjustments made during the preparation of our consolidated financial statements for
2016.


Alere Inc. and Subsidiaries

Preliminary Unaudited Reconciliation of Net Income (Loss) to Non-GAAP EBITDA

(in thousands)






Three Months Ended December 31,


2016


2015





Net Income (loss) (1)

$ (117,005)


$ (19,077)

Less: Income from discontinued operations, net of tax

-


2,736

Loss from continuing operations

(117,005)


(21,813)





Adjustment related to acquired software license contracts

-


-

Income tax provision (benefit)

83,762


(51,146)

Depreciation and amortization

71,467


75,719

Interest, net

42,342


57,954

Non-cash stock-based compensation expense

10,681


6,795

Non-cash fair value adjustments to acquisition-related contingent
consideration

(1,419)


(5,703)

Impairment and (gain) loss on dispositions, net

(11,152)


8,132

Non-cash INRatio product recall expenses

-


21,100

Other

-


(40)

Non-GAAP Adjusted EBITDA

$ 78,676


$ 90,998





(1) Net income (loss) for the three months ended December 31, 2015 includes $16.7 million of cash costs associated with the voluntary withdrawal of InRatio product, restructuring charges of $4.3 million, $2.8 million of costs associated with business dispositions, $0.1 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA. The three months ended December 31, 2016 includes $22.1 million of Abbott integration costs, $14.3 million for a legal settlement accrual, $12.8 million of charges related to governmental investigations, non-interest related restructuring charges of $10.1 million, $0.5 million of cash costs associated with the voluntary withdrawal of InRatio product, and $0.1 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.


Twelve Months Ended December 31,


2016


2015





Net Income (loss) (1)

$ (140,121)


$ 204,065

Less: Income from discontinued operations, net of tax

-


219,513

Loss from continuing operations

(140,121)


(15,448)





Adjustment related to acquired software license contracts

-


877

Income tax provision (benefit)

35,376


(53,564)

Depreciation and amortization

285,884


309,684

Interest, net

168,320


212,551

Non-cash stock-based compensation expense

41,796


26,391

Non-cash fair value adjustments to acquisition-related contingent
consideration

(13,308)


(57,613)

Impairment and (gain) loss on dispositions, net

(33,683)


50,540

Non-cash INRatio product recall expenses

-


21,100

Other

-


622

Non-GAAP Adjusted EBITDA

$ 344,264


$ 495,139





(1)Net income (loss) for the twelve months ended December 31, 2015 includes $16.7 million of cash costs associated with the voluntary withdrawal of InRatio product, restructuring charges of $15.6 million, $9.3 million of costs associated with business dispositions, and $0.5 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA. The twelve months ended December 31, 2016 includes $60.3 million of Abbott integration costs, restructuring charges of $37.9 million, $35.2 million for a legal settlement accrual, $35.6 million of charges related to governmental investigations, $6.0 million of acquisition-related costs, $1.8 million of cash costs associated with the withdrawal of InRatio product and $1.0 million of costs associated with business dispositions which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.

Alere Inc. and Subsidiaries

Preliminary Unaudited Reconciliation of Non-GAAP Organic Revenue Growth

(in thousands)







Three Months Ended December 31,

% Change


2016

2015


2016 v. 2015






Net revenue

$ 596,809

$ 617,136


-3.3%

Impact of foreign currency exchange

7,830

-



Impact of acquisitions & dispositions

(1,453)

(8,234)








Non-GAAP organic net revenue

$ 603,186

$ 608,902


-0.9%






Arriva Revenue

(11,622)

(38,592)








Non-GAAP organic net revenue (excluding Arriva)

$ 591,564

$ 570,310


3.7%

















Twelve Months Ended December 31,

% Change


2016

2015


2016 v. 2015






Net revenue

$ 2,376,335

$ 2,455,615


-3.2%

Impact of foreign currency exchange

40,543

-



Impact of acquisitions & dispositions

(13,984)

(60,414)








Non-GAAP organic net revenue

$ 2,402,894

$ 2,395,201


0.3%






Arriva Revenue

(99,887)

(148,538)








Non-GAAP organic net revenue (excluding Arriva)

$ 2,303,007

$ 2,246,663


2.5%

Alere Inc. and Subsidiaries

Preliminary Unaudited Consolidated Statements of Cash Flows

(in thousands)








For The Year Ended December 31,


2016


2015


2014




Cash Flows from Operating Activities:






Net income (loss)

$ (140,121)


$ 204,065


$ (33,123)

Income from discontinued operations, net of tax


219,513


138,318

Income (loss) from continuing operations

(140,121)


(15,448)


(171,441)

Adjustments to reconcile net income (loss) from continuing operations to net cash provided
by operating activities:






Non-cash interest expense, including amortization of original issue discounts and deferred financing costs

13,369


12,831


16,233

Depreciation and amortization

285,608


309,264


336,029

Non-cash stock-based compensation expense

41,796


26,391


12,452

Tax benefit related to discontinued operations retained by Alere Inc.



9,845

Impairment of inventory

2,667


15,597


3,124

Impairment of long-lived assets

1,792


3,708


7,019

Loss on sale of fixed assets

3,551


3,925


6,545

Equity earnings of unconsolidated entities, net of tax

(50,505)


(15,530)


(17,509)

Deferred income taxes

(36,010)


(99,389)


12,254

Loss on extinguishment of debt


19,886


Impairment and net (gain) loss on business disposition

(3,810)


50,540


7,742

Other non-cash items

(463)


28,782


4,965

Non-cash change in fair value of contingent consideration

(13,309)


(59,871)


7,677

Changes in assets and liabilities, net of acquisitions:






Accounts receivable, net

26,698


(6,680)


(4,264)

Inventories, net

(13,655)


(63,935)


(67,532)

Prepaid expenses and other current assets

(19,921)


(5,295)


(51,998)

Accounts payable

4,362


(10,783)


47,851

Accrued expenses and other current liabilities

54,342


22,643


37,886

Other non-current assets and liabilities

23,329


(3,357)


13,254

Cash paid for contingent consideration

(430)


(6,315)


(22,077)

Net cash provided by continuing operations

179,290


206,964


188,055

Net cash provided by discontinued operations


318


43,468

Net cash provided by operating activities

179,290


207,282


231,523







Cash Flows from Investing Activities:






Increase in restricted cash

(4,721)


(13,715)


(5,446)

Purchases of property, plant and equipment

(67,694)


(90,778)


(100,562)

Proceeds from sale of property, plant and equipment

1,428


2,099


1,486

Cash received from business dispositions, net of cash divested

21,470


675,823


45,076

Cash paid for business acquisitions, net of cash acquired

(5,958)


(60,135)


(75)

Cash received from investments



198

Cash paid for equity investment

(184)



Proceeds from sale of equity investment

40,751



8,546

Cash received from sales of marketable securities

87


92


580

Cash received from equity method investments

16,989


26,136


980

Decrease (increase) in other assets

460


(1,794)


986

Net cash provided by (used in) continuing operations

2,628


537,728


(48,231)

Net cash used in discontinued operations


(209)


(8,972)

Net cash provided by (used in) investing activities

2,628


537,519


(57,203)







Cash Flows from Financing Activities:






Cash paid for financing costs

(29,187)


(16,188)


(1,528)

Cash paid for contingent consideration

(680)


(14,223)


(32,902)

Cash paid for dividends

(21,292)


(21,293)


(21,293)

Proceeds from issuance of common stock, net of issuance costs

18,934


79,185


51,555

Proceeds from issuance of short-term debt


1,511


806

Proceeds from issuance of long-term debt

459


2,162,162


58

Payments on short-term debt

(1,722)


(25,584)


Payments on long-term debt

(198,316)


(2,656,386)


(65,122)

Net proceeds (payments) under revolving credit facilities

126,017


(127,536)


(42,522)

Excess tax benefits on exercised stock options



972

Principal payments on capital lease obligations

(4,032)


(5,618)


(6,085)

Purchase of non-controlling interest



(623)

Other


(8,937)


Net cash used in continuing operations

(109,819)


(632,907)


(116,684)

Net cash used in discontinued operations


(76)


(1,471)

Net cash used in financing activities

(109,819)


(632,983)


(118,155)

Foreign exchange effect on cash and cash equivalents

(7,084)


(11,379)


(16,312)

Net increase in cash and cash equivalents

65,015


100,439


39,853

Cash and cash equivalents, beginning of period - continuing operations

502,200


378,461


355,431

Cash and cash equivalents, beginning of period - discontinued operations


23,300


6,477

Cash and cash equivalents, end of period

567,215


502,200


401,761

Less: Cash and cash equivalents of discontinued operations, end of period



23,300

Cash and cash equivalents of continuing operations, end of period

$ 567,215


$ 502,200


$ 378,461

Alere Inc. and Subsidiaries

Preliminary Unaudited Supplemental Financial Information

(in thousands, except per share amounts)




















Three months ended December 31, 2016


Cost of Net
Revenue


Research and
Development


Selling, General
& Administrative


Impairment,
net of loss on
disposition


Interest and
other income,
net


Provision for
income taxes


Equity earnings of
unconsolidated entities,
net of tax


Net Income1

















Amortization of acquisition-related intangible assets

$ 12,281


$ 922


$ 31,384


$ -


$ -


$ -


$ -


$ (44,587)

Restructuring charges

2,090


512


7,535


-


-


-


-


(10,136)

Impairment Charges

-


-


193


-


-


-


-


(193)

Stock-based compensation expense

518


531


9,633


-


-


-


-


(10,681)

Acquisition-related costs

-


-


72


-


-


-


-


(72)

Fair value adjustments to acquisition-related contingent consideration

-


-


(1,419)


-


-


-


-


1,419

Costs associated with potential business dispositions

-


-


42


-


-


-


-


(42)

Impairment and (gain) loss on disposition, net

-


-


-


-


-


-


(11,152)


11,152

Amortization - Unconsolidated Subs

-


-


-


-


-


-


46


(46)

Audit and legal fees related to on-going governmental investigations

-


-


12,893


-


1,697


-


-


(14,590)

Abbott transaction related expenses

-


-


22,064


-


-


-


-


(22,064)

INRatio recall expense

2,481


-


(1,300)


-


-


-


-


(1,181)

Legal settlement accrual

-


-


14,300


-


-


-


-


(14,300)

Income tax effects on items above

-


-


-


-


-


72,986


-


(72,986)

Total of Supplemental Information

$ 17,370


$ 1,965


$ 95,398


$ -


$ 1,697


$ 72,986


$ (11,106)


$ (178,309)

















Impact of above items on EPS numerator















$ (5,367)

Impact of above items on EPS denominator















(11,301)

















1) All impacts are shown as pre-tax with aggregate tax effect displayed as "Income tax effects on items above".














































Twelve months ended December 31, 2016


Cost of Net Revenue


Research and Development


Selling, General & Administrative


Impairment, net of loss on disposition


Interest and other income, net


Provision for income taxes


Equity earnings of unconsolidated entities, net of tax


Net Income1

















Amortization of acquisition-related intangible assets

$ 49,616


$ 3,685


$ 127,253


$ -


$ -


$ -


$ -


$ (180,553)

Restructuring charges

5,991


4,052


27,831


-


-


-


-


(37,874)

Impairment Charges

85


-


193


-


-


-


-


(278)

Stock-based compensation expense

2,054


1,904


37,838


-


-


-


-


(41,796)

Acquisition-related costs

-


5,000


1,030


-


-


-


-


(6,030)

Fair value adjustments to acquisition-related contingent consideration

-


-


(13,308)


-


-


-


-


13,308

Costs associated with potential business dispositions

7


-


995


-


-


-


-


(1,002)

Impairment and (gain) loss on disposition, net

-


-


-


(3,810)


-


-


(29,873)


33,683

Amortization - Unconsolidated Subs

-


-


-


-


-


-


275


(275)

Audit and legal fees related to on-going governmental investigations

-


-


35,615


-


4,509


-


-


(40,125)

Abbott transaction related expenses

-


-


60,266


-


-


-


-


(60,266)

INRatio recall expense

4,581


-


-


-


-


-


-


(4,581)

Legal settlement accrual

-


-


35,175


-


-


-


-


(35,175)

Income tax effects on items above

-


-


-


-


-


(19,303)


-


19,303

Total of Supplemental Information

$ 62,333


$ 14,641


$ 312,888


$ (3,810)


$ 4,509


$ (19,303)


$ (29,598)


$ (341,660)

















Impact of above items on EPS numerator















$ (1,035)

Impact of above items on EPS denominator















(2,279)

















1) All impacts are shown as pre-tax with aggregate tax effect displayed as "Income tax effects on items above".











Alere Inc. and Subsidiaries

Preliminary Unaudited Reconciliation of Non-GAAP Organic Revenue Growth

(in thousands)







Three Months Ended March 31,

% Change


2017

2016


2017 v. 2016






Net revenue

$ 588,216

$ 586,940


0.2%

Impact of foreign currency exchange

4,770

-



Impact of acquisitions & dispositions

(900)

-








Non-GAAP organic net revenue

$ 592,085

$ 586,940


0.9%






Arriva Revenue

(3,039)

(35,143)








Non-GAAP organic net revenue (excluding Arriva)

$ 589,046

$ 551,797


6.8%

SOURCE Alere Inc.

Related Links

www.alere.com

Original Source: https://www.newswire.com/news/alere-announces-update-on-form-10-k-and-provides-preliminary-unaudited

What Next?

Related Articles

Leave a Reply

Submit Comment